SMS Pharma.

Which are the latest news on SMS Pharma.?

Why is SMS Pharmaceuticals Ltd falling/rising?

As of 05-Sep, SMS Pharmaceuticals Ltd's stock price has risen to Rs 392.70, up 4.93%, driven by strong performance against the benchmark Sensex and impressive returns over various time frames. Despite a decline in investor participation, the stock shows strong momentum and remains liquid for trading.

As of 05-Sep, SMS Pharmaceuticals Ltd is experiencing a rise in its stock price, currently at Rs 392.70, reflecting an increase of Rs 18.45 or 4.93%. This upward movement can be attributed to several factors highlighted in the recent performance data. <BR><BR>The stock has outperformed the benchmark Sensex, showing a remarkable 10.50% increase over the past week, while the Sensex has declined by 0.97%. Over the last month, SMS Pharmaceuticals has also demonstrated resilience with an 8.03% gain compared to a 2.44% drop in the Sensex. Year-to-date, the stock has surged by 26.62%, significantly outperforming the Sensex's decline of 10.21%. Furthermore, the stock has shown impressive long-term performance, with a 68.36% increase over the past year and a staggering 206.68% rise over the last three years.<BR><BR>Today's performance indicates that SMS Pharmaceuticals has outperformed its sector by 5.57%, and it has been on a consecutive gain streak for the last three days, accumulating a total return of 7.16% during this period. The stock reached an intraday high of Rs 398.3, reflecting a 6.43% increase at its peak today. Additionally, it is trading above its moving averages across various time frames, indicating strong momentum.<BR><BR>However, it is important to note that there has been a decline in investor participation, with delivery volume dropping by 67.81% compared to the five-day average. Despite this, the stock remains liquid enough for trading, suggesting that the current price rise is supported by strong market interest, even if participation has waned.<BR><BR>In summary, the rise in SMS Pharmaceuticals Ltd's stock price can be attributed to its strong performance relative to the market and sector, impressive returns over various time frames, and positive momentum indicators, despite some concerns regarding investor participation.

Who are in the management team of SMS Pharma.?

The management team of SMS Pharma includes P Ramesh Babu (Chairman & Managing Director), P Sarath Kumar, Thummala Neelaveni, Shravan Kudaravalli, and Sarvepalli Srinivas (all Independent Directors), Vamsi Krishna Potluri (Executive Director), and Thirumalesh Tumma (Company Secretary & Compliance Officer).

The management team of SMS Pharma includes the following individuals:<BR><BR>1. **P Ramesh Babu** - Chairman & Managing Director<BR>2. **P Sarath Kumar** - Independent Director<BR>3. **Thummala Neelaveni** - Independent Director<BR>4. **Shravan Kudaravalli** - Independent Director<BR>5. **Sarvepalli Srinivas** - Independent Director<BR>6. **Vamsi Krishna Potluri** - Executive Director<BR>7. **Thirumalesh Tumma** - Company Secretary & Compliance Officer<BR><BR>If you need more information about any specific member or their roles, feel free to ask!

What does SMS Pharma. do?

SMS Pharmaceuticals Ltd manufactures Active Pharma Ingredients and intermediates in the pharmaceutical sector. As of June 2026, it reported net sales of 207 Cr and a net profit of 21 Cr, with a market cap of INR 3,324 Cr.

Overview:<BR>SMS Pharmaceuticals Ltd is engaged in the manufacturing of Active Pharma Ingredients and their intermediates within the Pharmaceuticals & Biotechnology industry, categorized as a Small Cap company.<BR><BR>History:<BR>Incorporated in December 1987, SMS Pharmaceuticals has maintained its status as a manufacturer in the pharmaceutical sector. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 207 Cr (Quarterly Results - Jun 2026)<BR>- Net Profit: 21 Cr (Quarterly Results - Jun 2026)<BR>- Market Cap: INR 3,324 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: 34.00<BR>- Industry P/E: 37<BR>- Dividend Yield: 0.11%<BR>- Debt Equity: 0.41<BR>- Return on Equity: 12.98%<BR>- Price to Book: 4.23<BR><BR>Contact Details:<BR>Address: 19 III Rd 71 Opp Bharatividya, Bhavan Public Sch Jubilee Hill Hyderabad Telangana : 500096<BR>Tel: 91-40-66288888<BR>Email: info@smspharma.com<BR>Website: http://www.smspharma.com

Who are the peers of the SMS Pharma.?

SMS Pharma's peers include Unichem Labs, Gufic BioScience, Aarti Drugs, Novartis India, Kwality Pharma, Advanced Enzyme, Ind-Swift Labs, Solara Active, Dishman Carbogen, and Zota Health Care. In terms of management risk, growth, and capital structure, Novartis India stands out positively, while Ind-Swift Labs has the highest 1-year return at 278.73%, and SMS Pharma's return is 56.83%.

Peers: The peers of SMS Pharma. are Unichem Labs., Gufic BioScience, Aarti Drugs, Novartis India, Kwality Pharma, Advanced Enzyme, Ind-Swift Labs., Solara Active, Dishman Carbogen, and Zota Health Care.<BR><BR>Quality Snapshot: Excellent management risk is observed at Novartis India, while Average management risk is found at Unichem Labs., Gufic BioScience, Aarti Drugs, Kwality Pharma, SMS Pharma., Advanced Enzyme, and the rest. Below Average management risk is seen at Ind-Swift Labs., Solara Active, Dishman Carbogen, and Zota Health Care. Growth is rated as Good for Unichem Labs. and Novartis India, while Below Average growth is noted for Gufic BioScience, Aarti Drugs, Kwality Pharma, SMS Pharma., Advanced Enzyme, Ind-Swift Labs., Solara Active, Dishman Carbogen, and Zota Health Care. Capital Structure is Excellent for Novartis India and Kwality Pharma, Good for Unichem Labs., Gufic BioScience, Aarti Drugs, and SMS Pharma., while Average is seen at Ind-Swift Labs. and Solara Active, and Below Average at Advanced Enzyme, Dishman Carbogen, and Zota Health Care.<BR><BR>Return Snapshot: Ind-Swift Labs. has the highest 1-year return at 278.73%, while Dishman Carbogen has the lowest at -32.34%. SMS Pharma.'s 1-year return of 56.83% is significantly higher than Dishman Carbogen's but lower than Ind-Swift Labs. Additionally, Advanced Enzyme and Dishman Carbogen have negative six-month returns.

How big is SMS Pharma.?

As of 31st August, SMS Pharmaceuticals Ltd has a market capitalization of 3,324.00 Cr, with recent net sales of 897.79 Cr and a net profit of 102.40 Cr.

As of 31st August, SMS Pharmaceuticals Ltd has a market capitalization of 3,324.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, SMS Pharmaceuticals reported Net Sales of 897.79 Cr and a Net Profit of 102.40 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 639.64 Cr and Total Assets of 1,152.68 Cr.

Are SMS Pharmaceuticals Ltd latest results good or bad?

SMS Pharmaceuticals Ltd's latest results show mixed performance: while there was a year-on-year net profit growth of 2.05% and a net sales increase of 5.56%, quarterly results revealed significant declines with net profit down 36.07% and net sales down 13.02%, raising concerns about the company's stability. Overall, the results lean more negative due to these quarterly challenges.

The latest results for SMS Pharmaceuticals Ltd present a mixed picture. On one hand, the company achieved a year-on-year net profit growth of 2.05% and a net sales increase of 5.56%, which are positive indicators. However, these gains are overshadowed by significant quarter-on-quarter declines, with net profit dropping by 36.07% and net sales decreasing by 13.02%.<BR><BR>Despite the operational challenges reflected in these quarterly results, SMS Pharmaceuticals demonstrated improved operating margins, with the operating margin rising to 19.79% from 16.77% in the previous quarter. This suggests effective cost management, even as revenues contracted.<BR><BR>Overall, while there are some positive aspects, the sharp declines in both profit and sales on a quarterly basis raise concerns about the company's stability and growth trajectory. Therefore, the results can be seen as more negative than positive, indicating underlying volatility and challenges that need to be addressed.

Should I buy, sell or hold SMS Pharmaceuticals Ltd?

When is the next results date for SMS Pharmaceuticals Ltd?

The next results date for SMS Pharmaceuticals Ltd is August 1, 2026.

The next results date for SMS Pharmaceuticals Ltd is scheduled for August 1, 2026.

Is SMS Pharma. technically bullish or bearish?

As of November 26, 2025, the trend is bullish with strong indicators like MACD and Bollinger Bands supporting this, although caution is advised due to a mildly bearish KST and Dow Theory signals.

As of 26 November 2025, the technical trend has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this position. The MACD is bullish on both the weekly and monthly time frames, and Bollinger Bands also indicate a bullish trend on both time frames. The daily moving averages are bullish, reinforcing the positive momentum. However, the KST shows a mildly bearish signal on the monthly, and Dow Theory indicates a mildly bearish stance on the weekly, which suggests some caution. Overall, the strength of the bullish trend is supported by the strong performance in the last week, with a return of 13.99% compared to the Sensex's 0.50%.

Is SMS Pharma. overvalued or undervalued?

As of November 26, 2025, SMS Pharma is considered overvalued with a PE ratio of 35.81, an EV to EBIT ratio of 26.04, and a Price to Book Value of 4.14, all indicating a premium compared to peers, despite a strong year-to-date return of 34.50%.

As of 26 November 2025, the valuation grade for SMS Pharma has moved from fair to expensive, indicating a shift in perception regarding its market value. The company is currently considered overvalued. Key ratios include a PE ratio of 35.81, an EV to EBIT ratio of 26.04, and a Price to Book Value of 4.14, all of which suggest a premium valuation compared to peers.<BR><BR>In comparison to its industry peers, SMS Pharma's PE ratio is higher than Sun Pharma's 37.53 and significantly above Cipla's more attractive 22.59. The PEG ratio of SMS Pharma stands at 1.26, which is on the higher side when compared to the industry average, further reinforcing the overvaluation stance. Notably, SMS Pharma has outperformed the Sensex with a year-to-date return of 34.50% compared to the Sensex's 9.56%, but this strong performance does not mitigate the concerns regarding its current valuation.

How has been the historical performance of SMS Pharma.?

SMS Pharma has shown consistent growth in net sales and profitability, with net sales increasing from 411.95 Cr in Mar'20 to 782.75 Cr in Mar'25, and profit after tax rising significantly to 67.40 Cr in Mar'25. Despite rising raw material costs and fluctuating cash flows, the company has improved operational efficiency and overall financial performance.

Answer:<BR>The historical performance of SMS Pharma shows a positive trend in net sales and profitability over the recent years, with significant fluctuations in certain metrics.<BR><BR>Breakdown:<BR>SMS Pharma's net sales have increased from 411.95 Cr in Mar'20 to 782.75 Cr in Mar'25, reflecting a consistent growth trajectory. Total operating income followed a similar pattern, rising from 464.91 Cr in Mar'19 to 782.75 Cr in Mar'25. However, the raw material costs also escalated, reaching 501.87 Cr in Mar'25, up from 259.50 Cr in Mar'20. Despite this increase in costs, the operating profit (PBDIT) rose to 145.22 Cr in Mar'25 from 93.49 Cr in Mar'19, indicating improved operational efficiency. Profit before tax saw a notable increase to 92.34 Cr in Mar'25, compared to 5.35 Cr in Mar'23, while profit after tax also improved significantly to 67.40 Cr in Mar'25 from just 3.88 Cr in Mar'23. The company's total assets grew from 607.91 Cr in Mar'20 to 1,152.68 Cr in Mar'25, alongside a rise in total liabilities from 607.91 Cr to 1,152.68 Cr over the same period. Cash flow from operating activities improved to 81.00 Cr in Mar'25, up from 22.00 Cr in Mar'23, although cash flow from investing activities showed a negative trend, reaching -123.00 Cr in Mar'25. Overall, SMS Pharma's financial performance indicates a robust growth in sales and profitability, despite rising costs and fluctuating cash flows.

Who are the top shareholders of the SMS Pharma.?

The top shareholders of SMS Pharma include the promoters, led by Ramesh Babu Potluri, and individual investors who hold 26.35% of the shares. Institutional investors, including mutual funds and foreign institutional investors, hold a combined total of 2.51%.

The top shareholders of SMS Pharma primarily include the promoters, who hold the majority of the shares. Notably, Ramesh Babu Potluri is the promoter with the highest holding, although his specific percentage is not detailed. <BR><BR>In terms of institutional investors, mutual funds hold a total of 2.43% through three different schemes, with Quant Mutual Fund - Quant Small Cap Fund being the highest public shareholder at 2.43%. Additionally, foreign institutional investors (FIIs) hold a minor stake of 0.08%. Individual investors collectively hold 26.35% of the company's shares. <BR><BR>Overall, the promoter group and individual investors are the key stakeholders in SMS Pharma.

Has SMS Pharma. declared dividend?

SMS Pharmaceuticals Ltd has declared a 40% dividend, amounting to ₹0.40 per share, with an ex-date of September 23, 2024. The company has shown strong long-term performance, with total returns of 477.41% over the past 5 years.

SMS Pharmaceuticals Ltd has declared a 40% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 40%<BR>- Amount per share: ₹0.40<BR>- Ex-date: 23 Sep 2024<BR><BR>Dividend Yield: 0.15%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -2.34%, with a dividend return of 0%, resulting in a total return of -2.34%.<BR><BR>Over the past year, the price return was 27.02%, the dividend return was 0.19%, leading to a total return of 27.21%.<BR><BR>In the last 2 years, the price return was 170.68%, with a dividend return of 0.76%, culminating in a total return of 171.44%.<BR><BR>For the 3-year period, the price return was 204.5%, the dividend return was 1.34%, resulting in a total return of 205.84%.<BR><BR>In the last 4 years, the price return was 55.42%, with a dividend return of 0.75%, leading to a total return of 56.17%.<BR><BR>Over the past 5 years, the price return was 475.4%, with a dividend return of 2.01%, resulting in a total return of 477.41%.<BR><BR>Overall, SMS Pharmaceuticals Ltd has declared a significant dividend, and the total returns over various periods indicate strong performance, particularly in the longer term, despite some fluctuations in the shorter periods.